Targeting KPNA2 Enhances Bortezomib Anti-myeloma activity Through Suppressing Non- Canonical NF-κB-Mediated Autophagy in Multiple Myeloma

Multiple myeloma is a cancer of the plasma cells, the specialized white blood cells in our bone marrow that produce antibodies to fight infection. In a healthy body, these cells are tightly controlled, but in this disease, they multiply uncontrollably, crowding out healthy blood cells and damaging bones. For decades, doctors have treated this condition with a drug called bortezomib, which works by jamming the cell's internal waste disposal system. When this system clogs, toxic proteins build up inside the cancer cells, causing them to self-destruct. While this treatment has saved many lives, the cancer often finds a way to adapt. The cells learn to survive the toxic buildup, clearing the debris and continuing to grow, which leads to the disease returning. Understanding exactly how these cells manage to survive this stress is the key to finding better ways to stop them.

A team of researchers at the First Affiliated Hospital of Nanchang University in China has uncovered a specific mechanism that allows these cancer cells to resist the drug. They focused on a protein called KPNA2, which acts like a delivery truck inside the cell, shuttling important instructions from the outer cytoplasm into the nucleus, where the cell's master control center resides. The scientists discovered that in patients with multiple myeloma, the levels of this delivery truck are significantly higher than in healthy individuals. Furthermore, the more of this protein a patient has, the more aggressive their disease tends to be, and the shorter their survival time. The researchers found that this protein is not just a marker of a bad outcome; it is an active driver that helps the cancer cells survive the very treatment meant to kill them.

To understand how this works, the team looked at what happens when they removed or blocked KPNA2 in cancer cells grown in the lab. Without this protein, the cells stopped growing as fast and became much more vulnerable to the drug bortezomib. The researchers traced the reason for this vulnerability to a survival process called autophagy. You can think of autophagy as the cell's internal recycling program, where it breaks down damaged parts to clear space and generate energy. When the drug bortezomib clogs the waste disposal system, the cancer cells usually ramp up this recycling program to clean up the mess and stay alive. The study showed that KPNA2 is the switch that turns this recycling program on. When KPNA2 is present, the cell efficiently activates its cleanup crew, allowing it to withstand the drug. When the researchers blocked KPNA2, the recycling program failed, the toxic waste piled up, and the cancer cells died.

The scientists then mapped out the exact path KPNA2 takes to give this order. They found that KPNA2 does not affect all cellular pathways equally. Instead, it specifically activates a particular signaling route known as the non-canonical NF-κB pathway. This pathway is a set of instructions that tells the cell to prepare for stress. KPNA2 acts as the transporter that moves the key components of these instructions, specifically proteins named p52 and RelB, from the outside of the nucleus into the control center. Once inside, these proteins turn on the genes responsible for the autophagy cleanup. The study confirmed that if the researchers blocked this specific signaling route, the cancer cells could no longer activate their recycling program, even if KPNA2 was present. This proved that KPNA2, the non-canonical NF-κB pathway, and the autophagy cleanup process are linked in a single chain of events that protects the cancer.

To see if this discovery could lead to a new treatment, the team tested a combination approach in mice that had human multiple myeloma tumors. They treated the mice with bortezomib alone, with a drug called ivermectin that blocks KPNA2, or with both drugs together. Ivermectin is an existing medication, but in this context, it was used to stop the KPNA2 delivery truck from working. The mice treated with the combination of both drugs showed the best results. Their tumors shrank significantly more than those treated with bortezomib alone. The researchers observed that blocking KPNA2 prevented the cancer cells from activating their survival recycling program, making them once again sensitive to the original drug. This suggests that adding a KPNA2 blocker to the standard treatment could help overcome the resistance that often develops.

The study also looked at data from human patients to confirm these findings. By analyzing bone marrow samples from people with multiple myeloma, the researchers found that those with high levels of KPNA2 were more likely to have advanced disease and to respond poorly to bortezomib treatment. In patients whose disease progressed despite treatment, the levels of this protein were notably higher than in those who achieved a complete response. This clinical evidence supports the idea that KPNA2 is a critical factor in how the disease behaves and how well it responds to therapy. The researchers concluded that KPNA2 serves as a vital bridge connecting the cell's transport system to its stress response, and that targeting this connection offers a promising new strategy to improve outcomes for patients who currently struggle with drug resistance.